Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
UCLA Clinical Genomics Center, |
RCV000197493 | SCV000255351 | likely pathogenic | Bethlem myopathy 1A | 2012-03-27 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000593438 | SCV000709570 | uncertain significance | not provided | 2017-06-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000197493 | SCV001581198 | pathogenic | Bethlem myopathy 1A | 2021-04-04 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has been observed in individual(s) with clinical features of autosomal dominant Bethlem myopathy (PMID: 25326637, 24134684). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 216911). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with aspartic acid at codon 699 of the COL6A2 protein (p.Gly699Asp). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and aspartic acid. |